


































0Carbohydrate Polymers 130 (2015) 133–140
Contents lists available at ScienceDirect
Carbohydrate  Polymers
j ourna l ho me  page: www.elsev ier .com/ locate /carbpol
ulticomponent  systems  with  cyclodextrins  and  hydrophilic
olymers  for  the  delivery  of  Efavirenz
lexandre  Couto  Carneiro  Vieiraa,1, Danilo  Augusto  Ferreira  Fontesa,
uise  Lopes  Chavesa,1, Lariza  Darlene  Santos  Alvesa, José  Lourenc¸ o  de  Freitas  Netoa,
onica  Felts  de  La  Roca  Soaresc,  Jose  L.  Soares-Sobrinhoc,∗, Larissa  Araújo  Rolima,b,
edro  José  Rolim-Netoa
Laboratório de Tecnologia Farmacêutica da Universidade Federal de Pernambuco, Rua Arthur de Sá, s/n, Cidade Universitária, 50, 740-521 Recife, PE, Brazil
Colegiado de Ciências Farmacêuticas da Universidade Federal do Vale do São Francisco (UNIVASF) Campus Petrolina I, Petrolina, PE, Brazil
Núcleo de Controle de Qualidade de Medicamentos e Correlatos – NCQMC da Universidade Federal de Pernambuco, Rua Arthur de Sá, s/n,
idade Universitária, 50, 740-521 Recife, PE, Brazil
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 30 March 2015
eceived in revised form 21 April 2015
ccepted 23 April 2015
vailable online 1 May  2015
eywords:
ow solubility
a  b  s  t  r  a  c  t
Efavirenz  (EFZ) is  one  of  the  most  used  drugs  in the treatment  of  AIDS  and  is  the  ﬁrst antiretroviral  choice.
However,  since  it  has  low  solubility,  it does  not  exhibit  suitable  bioavailability,  which  interferes  with its
therapeutic  action  and  is  classiﬁed  as a class  II drug  according  Biopharmaceutical  Classiﬁcation  System
(low  solubility  and  high  permeability).  Among  several  drug  delivery  systems,  the  multicomponent  sys-
tems  with  cyclodextrins  and  hydrophilic  polymers  are  a promising  alternative  for  increasing  the aqueous
solubility  of the drug.  The  present  study  aimed  to  develop  and  characterize  in  a  ternary  system  of  EFZ,




dissolution  rate  which  was  greater  than  80%  and  was characterized  by  DSC,  TG,  XRD,  FT-IR  and  SEM.  The
use  of  the  ternary  system  (EFZ,  MCD and  PVP  K30  1%)  proved  to be a viable,  effective  and  safe delivery
of  the  drug.  The  addition  of  the  hydrophilic  polymer  appeared  to be suitable  for the  development  of  a
solid  oral  pharmaceutical  product,  with  possible  industrial  scale-up  and  with  low  concentration  of  CDs
(cyclodextrins).. Introduction
Oral ingestion is the most convenient and commonly employed
oute of drug delivery due to its easy administration, high patient
ompliance, cost-effectiveness, least sterility constraints, and ﬂex-
bility in the design of the dosage form (Savjani, Gajjar, & Savjani,
012).
However, the major challenge during the design of oral dosage
orms lies in their poor bioavailability (Chaves, Vieira, Reis,
armento, & Ferriera, 2014). The oral bioavailability depends on
everal factors including aqueous solubility, drug permeability, dis-
olution rate, ﬁrst-pass metabolism, pre-systemic metabolism, and
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susceptibility to efﬂux mechanisms. However, the major issue that
leads to low oral bioavailability is poor solubility and low per-
meability (Chouhan & Saini, 2014; Gundogdu, Koksal, & Karasulu,
2012; Savjani et al., 2012).
Low aqueous solubility is the major problem encountered with
the formulation development of new chemical entities (Chaves
et al., 2014). More than 40% of new chemical entities developed
in the pharmaceutical industry are practically insoluble in water.
Poorly water-soluble drugs present slow drug absorption, and
lead to inadequate and variable bioavailability and gastrointestinal
mucosal toxicity (Kumar et al., 2011; Miletic, Kyriakos, Graovac, &
Ibric, 2013; Sharma, Soni, Kumar, & Gupta, 2009). This is a chal-
lenge especially for class II (low solubility and high permeability)
substances according to the BCS. In these cases, the bioavailability
may  be enhanced by increasing the solubility and dissolution rate
of the drug in the gastrointestinal ﬂuids (Krishnaiah, 2010; Kumar
et al., 2011; Rong et al., 2014; Savjani et al., 2012).
Among all solubility enhancement techniques, the generation
of inclusion complexes with cyclodextrins has been employed
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nd bioavailability of poorly water-soluble drugs (Pose-Vilarnovo,
odríguez-Tenreiro Sánchez, Diéguez Moure, Vila-Jato, & Torres-
abandeira, 2003; Rong et al., 2014).
Cyclodextrins (CDs) are naturally available water-soluble cyclic
ligosaccharides composed of -1,4-linked d-glucopyranose units
Ribeiro, Carvalho, Ferreira, & Veiga, 2005) arranged in a donut-
haped ring having a hydrophobic cavity and hydrophilic outer
urface (Savjani et al., 2012). This low polarity central cavity is able
o encapsulate, either partially or entirely, a great variety of guest
olecules of suitable size and shape resulting in a stable associ-
tion without formation of covalent bonds, resulting in an entity
nown as a host–guest complex or inclusion complex (Miletic et al.,
013; Mora et al., 2003; Ribeiro et al., 2005; Saenger, 1980; Soares-
obrinho et al., 2012), Unfortunately, the complexation efﬁciency
f cyclodextrins is rather low and, therefore, a signiﬁcant amount
f cyclodextrins is needed to solubilize a small amount of water-
nsoluble compounds. However, enhanced complexation can be
chieved by formation of ternary complexes (or co-complexes)
etween the drug molecule, cyclodextrin molecule and a third com-
onent. Moreover, recent works have shown that the addition of a
uitable third component can often signiﬁcantly improve both the
olubilizing and complexing abilities of cyclodextrins with several
rugs (Jug & Bec´irevic´-Lac´an, 2004; Mora et al., 2003).
For several reasons, including toxicology, dosage and cost, the
mount of cyclodextrins used in most of the formulations must
e limited. Therefore, it is important to develop strategies to
ncrease the effectiveness of cyclodextrin complexation that could
e reﬂected in a reduction in the amount of CD necessary in a partic-
lar drug formulation (Pose-Vilarnovo et al., 2003; Soares-Sobrinho
t al., 2012). To this end the use of water-soluble polymers, the
reparation of drug/CD/polymers (Du et al., 2012; Feng, Lu, Li,
 Huang, 2013; Loftsson, Frikdriksdóttir, Sigurkdardóttir, & Ueda,
994; Taupitz, Dressman, Buchanan, & Klein, 2013; Valero, Pérez-
evuelta, & Rodrıı´guez, 2003), multicomponent systems, or the
ormation of CD complexes of salts of acidic drugs have been
escribed. The use of polymers has been used, at great expense,
n recent years but the exact nature of the polymer CD interaction
s not known yet (Pose-Vilarnovo et al., 2003; Redenti, Szente, &
zejtli, 2001; Valero et al., 2003).
Despite being widely used in therapeutics, Efavirenz (EFZ) has
ery low oral bioavailability (40–45%) (Sathigari, Radhakrishnan,
avis, Parsons, & Babu, 2012). EFZ is crystalline, highly lipophilic
nd has been classiﬁed in the Biopharmaceutics Classiﬁcation Sys-
em as a class II compound with high permeability but low aqueous
olubility (∼3–9 g/mL) with dissolution, rate-dependent absorp-
ion (Chiappetta, Hocht, Taira, & Sosnik, 2011; Lindenberg, Kopp, &
ressman, 2004; Madhavi et al., 2011; Sathigari et al., 2012).
Different techniques have been used to enhance the solubil-
ty and dissolution rate of poorly soluble drugs in water such as
icronization, polymorphs, solid dispersions, complexation with
yclodextrins, polymeric and lipid nanoparticles, and salt forma-
ion (Alves et al., 2014; Chiappetta et al., 2011; Gaur, Mishra, Bajpai,
 Mishra, 2014; Leuner & Dressman, 2000; Paudel, Worku, Meeus,
uns, & Van den Mooter, 2013; Soares-Sobrinho et al., 2012).
Therefore, the aim of this study was to evaluate the inﬂuence of
he type of cyclodextrin on the properties of a poorly soluble model
rug, EFZ, as well as to evaluate the effect of a drug–CD–polymer
n the solubility of EFZ.
. Materials and methodsEfavirenz (Cristália®, Batch: 1289/07) was provided by
he Laboratório Farmacêutico de Pernambuco (LAFEPE). Methyl-
-cyclodextrin (MCD) was provided by Roquette® (Spain),
olyvinylpyrrolidone (PVP) K-30 by BASF®, Germany; and PVP K30lymers 130 (2015) 133–140
by ISO Brazil® (lot 05500138511V06/08), and sodium lauryl sulfate
(SLS) by Vetec® (lot 0806072). The solutions were prepared using
ultrapure water (MILLI Q) and ﬁltered through a 0.22 m Millipore®
membrane (Millipore Corp, Billerica, MA). Other reagents and
chemicals were of analytical reagent grade.
2.1. Phase-solubility diagram
The phase-solubility diagrams were performed similar to those
performed by Soares-Sobrinho et al. (2012).
In order to select the best cyclodextrin, a phase-solubility dia-
gram with different types of cyclodextrins (CDs) was constructed.
Aqueous solutions of CD, MCD, HPCD and RMCD were pre-
pared at the concentration range of between 1 and 20 mM,  and
between 1 and 15 mM for CD due its low solubility (Loftsson &
Brewster, 1996). An excess amount of EFZ (∼30 mg)  was added to
each test tube containing 10 mL  deionized water. The test tubes
were sealed and shaken for 5 days in an oscillating water bath ther-
mostatically controlled at 25 ± 0.5 ◦C and, then, the content of each
test tube was  ﬁltered through a 0.22 m cellulose membrane ﬁlter.
The ﬁltrate was  suitably diluted and analyzed spectrophotometri-
cally at 247 nm by a method previously developed and validated
(Alves et al., 2010). The experiment was performed in triplicate.
Afterwards, in order to evaluate the interactions of cyclodex-
trins and a hydrophilic polymer in the increasing of EFZ solubility,
another phase-solubility diagram was  constructed. For this pur-
pose, MCD was used as a model at a ﬁxed concentration (10 mM)
in aqueous solutions while increasing concentrations (0.05–1%,
w/w) of a hydrophilic polymer (PVP K30) were used.
2.2. Preparation of inclusion complexes in a solid state
For the obtainment of the solid inclusion complexes, EFZ/MCD
(mol/mol) was  used with PVP-K30 in crescent concentrations (1%,
5%, 10% and 30%).
2.2.1. Preparation of physical mixtures (PMs)
EFZ and MCD were precisely weighed in an equimolar ratio
(10 mM)  and PVP-K30 was used in different weight ratios (1, 5,
10 and 30%) in relation to the total amount of the binary sys-
tems EFZ:MCD. Subsequently, the mixtures were pulverized with
a mortar and a pestle and were sifted through a 250 m mesh and
stored in airtight glass desiccators under a vacuum.
2.2.2. Preparation of the kneading (KN) complexes
The KN system was  prepared similarly to the physical mixture,
supplemented by the slow addition of an ethanol/water solution
(1:1, v/v) until homogeneous (Alves et al., 2014) in order to obtain
a moist bulk, characteristic of the kneading process. The samples
were dried at 50 ◦C for 60 min; the resulting solid inclusion com-
plex was  sifted through a 250 m sieve and then the products were
placed in vials and stored in an airtight glass desiccator under a
vacuum. The kneading process has important advantages as sim-
ple obtention, high-yielding, and easy scale up. Nowadays, it is still
the most commonly used method in the pharmaceutical industry
(Pupe et al., 2011; Soares-Sobrinho et al., 2012).
2.3. Characterization of the solid state complex
2.3.1. Dissolution proﬁle
Studies of drug release were performed in quadruplicate usingdissolution test equipment, employing the apparatus paddle at
50 rpm in a dissolution medium of water with 0.5% sodium lau-
ryl sulfate (SLS) (900 mL) at 37 ± 0.5 ◦C (Alves et al., 2014; Pinto,
Cabral, & Sousa, 2014).




































Complexation constants (Kc1:1) for EFZ:CDs and EFZ:CDs:PVP K30 determined by
solubility phase diagram.
Systems binary and ternary Slope Intercept Kc1:1 (M−1)
EFZ:CD 0.00485 0.02613 184.7
EFZ:CD 0.00630 0.02918 214.5
EFZ:RMCD 0.00729 0.03032 238.7
EFZ:HPCD 0.00956 0.02508 377.5
EFZ:MCD  0.01060 0.02884 363.6
EFZ:HPCD:PVP K30 0.03024 0.14246 218.9
EFZ:MCD:PVP K30 0.05234 0.13256 416.6A.C.C. Vieira et al. / Carbohyd
Capsules containing the equivalent of 30 mg  of drug were used.
liquots of 4 mL  were withdrawn at 15, 30, 45, and 60 min, and the
ame volume of dissolution medium was replaced. The samples
ere ﬁltered through a 0.45 m porosity membrane and properly
uantiﬁed.
.3.2. X-ray powder diffraction (XRD)
The diffraction patterns of samples were obtained using an X-ray
iffractometer (Siemens®, D-5000), equipped with a copper anode.
he samples were analyzed in the 2 angle range of 2–60 at a scan
peed of 0.02◦ 2/s. The samples were prepared in glass holders
ith a thin layer of powder material without solvent.
.3.3. Fourier transform infrared (FT-IR)
The infrared spectrum was obtained using a device equipped
ith a selenium attenuated total reﬂectance (ATR) crystal
PerkinElmer®, Spectrum 400). The samples to be analyzed were
ransferred directly to the ATR compartment and the result was
aken to be the average of 10 scans. The micrographs were obtained
or the range of 650–4000 cm−1 at a resolution of 4 cm−1.
.3.4. Differential scanning calorimetry (DSC)
DSC studies were carried out using differential scanning
alorimeter (DSC 60, Shi-madzu, Japan). The samples, with the
quivalent of 2 mg  of drug (±0.2 mg), were hermetically sealed in
luminum pans and heated at a constant rate of 10 ◦C min−1 at a
emperature range of 25–200 ◦C. An inert atmosphere was main-
ained by purging nitrogen gas at a ﬂow rate of 50 mL  min−1.
.3.5. Thermogravimetry (TG)
Thermoanalytical characterization using TG was performed in
riplicate by a, Shimadzu®TGA thermobalance, model Q60, in a
itrogen atmosphere with a ﬂow of 50 mL  min−1. The sample mass
as of about 4 mg  (±0.4) of EFZ, packed in an aluminum oxide cru-
ible at a temperature range of 25–500 ◦C at the heating rate of
0 ◦C min−1.
.3.6. Scanning electron microscopy (SEM)
The samples were sputter-coated with gold using a vacuum
vaporator (Baltec® SCD 050 metalizer) and examined using a scan-
ing electron microscope (Jeol® JSM-5900) at 15 kV accelerating
oltage.
. Results and discussion.1. Phase-solubility diagram
Phase-solubility studies of binary systems (EFZ:CDs) (Fig. 1),
ere performed in order to observe the effect of the complexation
Fig. 1. Phase-solubility diagram with different types of cyclodextrins (ability of different types of cyclodextrin systems. In accordance
with the results, it was observed that the cyclodextrin that
increased EFZ solubility better was MCD (from 9 g/mL to
75,227 g/mL) (Loh, Tan, & Peh, 2014).
In addition, it is well established that from these diagrams it is
possible to estimate the stoichiometry involved (Jullian et al., 2008;
Xu et al., 2014). The experimental results demonstrated that the
obtainment of inclusion complexes with a typical proﬁle and sug-
gested an occurrence of soluble complexes with 1:1 stoichiometry
(Sathigari et al., 2009).
The complexation constants (Kc) (Jug, Kosalec, Maestrelli, &
Mura, 2011) are given in Table 1. Kc1:1, calculated on the basis of
the solubility phase diagram, shows that the formation of inclu-
sion complexes and ternary complexes are stable with EFZ, since,
according to Jun et al. (2007), the association constants for drugs
with CDs appear in the 50–2000 M−1 band.
Regarding the ternary complexes, the choice of PVP K30 as a
hydrophilic polymer to increase the solubility of EFZ had been
already studied (Alves et al., 2014; Soares-Sobrinho et al., 2012).
Besides, the effect of the hydrophilic polymer association with
cyclodextrins to increase the solubility of insoluble drugs is
well established in the literature (Cappello, Carmignani, Iervolino,
Immacolata La Rotonda, & Fabrizio Saettone, 2001; de Melo et al.,
2013; Soares-Sobrinho et al., 2012).
Increasing concentrations of MCD have led to a proportional
increase in EFZ solubility, as noted, from 9 g/mL to 82.12 g/mL.
According to the results of the experiments, the use of PVP K30 at
1% promoted the best improvement in the solubility of EFZ.
This relationship could be explained by the electrostatic inter-
action, i.e., Van der Waals and hydrogen bonds, that may  be formed
due to the susceptible groups of EFZ and MCD, favoring the sta-
bility of the complex (Ribeiro et al., 2005).
For subsequent studies, the MCD at 10 mM was chosen as a
model, as well as PVP K30 at 1%, for the characterization of the
solid state.
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.2. Characterization of the solid state complex
.2.1. In vitro dissolution studies
The dissolution proﬁles of EFZ, the kneading solid multi-
omponent (KN) with 1, 5, 10 and 30% and the respective physical
ixtures are presented in Fig. 2. In accordance with the results,
t is clear that the dissolved fractions of EFZ decrease with the
ncrease of the amount of PVP K30, in the case of the kneaded
ompounds. What was not observed, in the case of physical mix-
ures, was exactly the opposite. It means that the kneading process
romoted a higher interaction between the three compounds:
Fig. 2. In vitro dissolution studies: EFZ, physical mixtures and kneadin
Fig. 3. Diffractogram of the separate excipients EFZ, MCDlymers 130 (2015) 133–140
drug–cyclodextrin–polymer, explained by the strong non-covalent
interactions, already well described in the literature (Brewster &
Loftsson, 2007; Jansook, Kurkov, & Loftsson, 2010). These behaviors
of prolonged delivery of EFZ with 30% and 10% of PVP K30 is associ-
ated with the swelling phenomenon, a characteristic of hydrophilic
polymers, in which larger amounts leads to the formation of a high
viscosity gel layer around the powdered products which could con-
trol the diffusivity of the dissolved drug to the dissolution media
(Nokhodchi, Raja, Patel, & Asare-Addo, 2012; Ribeiro et al., 2005).
Although, in all cases, including PM,  the solid complexes were able
to improve the solubility of EFZ compared to the pure drug, which
g at different concentrations of PVP K30 (1%, 5%, 10% and 30%).













pA.C.C. Vieira et al. / Carbohyd
ay  be explained by the decrease in the crystallinity of the ﬁnal
ompounds due to the presence of PVP K30.
On the other hand, the KN complex with 1% PVP K30 promoted
he best increase in the solubility and delivery of EFZ. In 30 min,
ore than 80% of the total drug was delivered, against less than
5% compared with EFZ alone. In this case, the PVP K30 acted as a
o-complexing agent, increasing the hydrophilic potential of MCD
de Melo et al., 2013; Ghosh, Biswas, & Ghosh, 2011).
.2.2. X-ray diffraction (XRD)
For the further characterization of the complexes obtained, the
est system was chosen as a model: EFZ:MCD:PVP K30 1%.
XRD patterns for solid compounds are mainly used for eval-
ating changes in crystalline structure of the drug (Fig. 3). The
FZ diffractogram, according to the literature (Alves et al., 2014),
resented a very distinct peak at 2 of 6.24◦, and others of lower
Fig. 4. Infrared spectra of the separate excipients EFZ, MCD
Fig. 5. DSC thermograms of the separate excipients EFZ, MClymers 130 (2015) 133–140 137
intensity between the range of 10◦ and 30◦. Regarding the XRD pat-
terns of PVP K30 and MCD, both were characterized by a complete
absence of peaks, due to their amorphous compound characteristic
(Ghosh et al., 2011).
Regarding the ternary systems, it was  observed that physical
mixtures were basically an overlap of the EFZ, PVP K30 pat-
tern proﬁles and MCD, with a decrease in the intensity of the
main peak of EFZ at 6.24◦. In the case of KN compounds, a slight
increase in the secondary crystalline peaks, between 10◦ and 30◦,
was observed, which did not, necessarily, have to do with the
crystallinity of EFZ, but with the new shapes that the solid com-
plexes exhibited, as seen in the microscopies. This fact reinforces
the results obtained in the dissolution proﬁle which indicates a
strong interaction between the constituents of the ternary sys-
tem, revealing that, although KN is not completely amorphous, it
does not affect the increased solubility of EFZ. This behavior of a
, PVP K30 and the ternary KN 1% and PM 1% systems.
D, PVP K30 and the KN1% and PM 1% ternary systems.
138 A.C.C. Vieira et al. / Carbohydrate Polymers 130 (2015) 133–140
Fig. 6. TG curves of the separate excipients EFZ, MCD, PVP K30 and the KN1% and PM1% ternary systems.
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light increase in the crystallinity of KN complexes was already
escribed.
.2.3. Fourier transform infrared (FT-IR)
The KN and PM spectra (Fig. 4) were similar in relation to the
ecrease in the intensity of the EFZ main bands, especially the ones
elated to the C O stretching (1742 cm−1) besides highlighting the
resence of the bands concerning the stretch O H of the PVP K30
3419 cm−1) and MCD (3297 cm−1) which overlaps the N H band
f EFZ (3314 cm−1. Simultaneously, all the bands of the spectra
elated to the C H stretching (2952 cm−1) and C O (1647 cm−1)
f PVP K30 were always present at a lower intensity. Additionally,
e noted that the stretch vibration of the C C (2249 cm−1) of EFZ
s practically absent in the KN system, suggesting a possible com-
lexation with the MCD within the cyclopropane group of EFZ.
he stretch vibration C C in the PM (2249 cm−1) was  still present,
ut at a lower intensity, due to the proportionally lower amount
f drug in the system. This suggests that the kneading process
ay  induce the formation of a complex between EFZ:MCD, since
uring the preparation of the PM no addition of water occurred,
hich is essential to obtain a complex. In addition, with the spec-
ra obtained, it is clear that in both ternary systems (PM and KN)
ntermolecular interactions between PVP K30, and the MCD EFZ,
specially hydrogen bonding, are strongly present (Mura, Faucci, &
ettinetti, 2001; Soares-Sobrinho et al., 2012).
.2.4. Differential scanning calorimetry (DSC)
The EFZ thermograms, obtained by DSC, showed an endother-
ic  event in the range between 123.31 and 145.20 ◦C (DH = 41.7 J/g)
orresponding to the melting of the drug. On the other hand, the
VP K30 thermograms showed a discrete endothermic event in a
road range between 50 and 120 ◦C (peaking at 104.21 ◦C) corre-
ponding to the evaporation of water as can be seen in Fig. 5. The
ame event can be observed for MCD in the range between 40◦
nd 130 ◦C.
The DSC curve of the PM showed an endothermic event between
63.3 ◦C and 171.5 ◦C (226.1 J/g), which melting point was  shifted
nd extended to a higher temperature comparing to the pure drug.
 similar event can be observed in the KN curve, which showed an
ndothermic event between 160.6 ◦C and 168.7 ◦C (116.69 J/g).
Hence, it is suggested that the presence of MCD and PVP
30 hinder the EFZ melting process, leading to both its shift to a
igher temperature and enlargement of the peak, with consequent
ncreased energy involved. Thus, it is suggested that the system
ives stability to the drug, which can be conﬁrmed by TG analysis.
.2.5. Thermogravimetry (TG)
It can be seen that in the PM as in the KN the degradation
teps are the sum of the individual degradation of EFV, MCD
nd PVP K30 (Fig. 6). In the PM decomposition event of EFZ
Tonset = 224.0 ◦C) it occurred at lower temperatures when com-
ared to isolated EFZ (Tonset = 231.9 ◦C). The same does not occur
n KN, when the decomposition process was shifted to higher tem-
eratures (Tonset = 272.6 ◦C) compared with EFZ.
Furthermore, the percentage of EFZ weight loss was  lower for
N (78%) when compared to the PM (81%), demonstrating that
he product obtained by the kneading technique provided greater
tability to EFZ (Freitas et al., 2012).
.2.6. Scanning electron microscopy (SEM)
Through the SEM images, the crystalline form of EFZ can be
bserved with orthorhombic crystals of an irregular shape (Fig. 7A
nd B), while PVP K30 (Fig. 7C and D) and MCD (Fig. 7E and F) are
pherical particles.
In electron micrographs of the PM (Fig. 7G and H), we  could
ee the permanence of EFZ in its crystalline form, despite beinglymers 130 (2015) 133–140 139
only superﬁcially adhered to PVP K30 and MCD, which continued
with the same morphology. This adherence does not occur with
KN (Fig. 7I and J), where uniform particles were observed, demon-
strating changes in both the original forms of EFZ as the other
constituents of the ternary system. Regarding KN, it can also be
observed that crystals of the drug are sometimes partially, hereby
fully inserted, in the matrix, maintaining the system with some
crystalline character, as detected in the XRD and DSC characteriza-
tion (Ghosh et al., 2011).
4. Conclusion
The results demonstrate a superior water solubility of the multi-
component system EFZ:MCD:PVP K30 in the concentration of 1%
against the inclusion complex EFZ:MCD at the same molar ratio.
The use of the KN technique to obtain the ternary solid state system,
permitted the formation of a uniform, substantially non-crystalline
particle, which increased the dissolution rate of EFV, and provided
an increase in the stability of the drug as demonstrated by ther-
mal  analysis, with strong electrostatic interactions between the
PVP K30 and MCD, as seen by FT-IR.
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